Tech Company Financing Transactions
Targepeutics Funding Round
On 7/25/2025, Targepeutics raised funding from Yuvaan Tiwari Foundation.
Transaction Overview
Company Name
Announced On
7/25/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to directly support the advancement of GB13, its lead drug candidate, into clinical trials for the treatment of diffuse intrinsic pontine glioma (DIPG).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1214 Research Blvd. 1011
Hummelstown, PA 17036
USA
Hummelstown, PA 17036
USA
Phone
Website
Email Address
Not Recorded
Overview
The majority of current cancer therapies kill tumor cells but also kill normal cells, creating unwanted toxicities and side effects. As a biopharmaceutical company, we have found a targeted way to attack only tumor cells. GB-13 is the lead compound in this new direction. We are working to advance GB-13 to clinical trials where new therapies are in desperate need including glioblastoma, diffuse midline glioma and soft tissue sarcomas.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/25/2025: OSL venture capital transaction
Next: 7/25/2025: Maro venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs